Filing Details

Accession Number:
0001179110-11-009693
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-06-15 18:30:27
Reporting Period:
2011-06-14
Filing Date:
2011-06-15
Accepted Time:
2011-06-15 18:30:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1005201 Depomed Inc DEPO Pharmaceutical Preparations (2834) 943229046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1415245 Tammy Cameron 1360 O'Brien Dr.
Menlo Park CA 94025
Vp, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-06-14 6,579 $8.24 3,960 No 4 S Direct
Common Stock Acquisiton 2011-06-14 1,354 $1.83 5,314 No 4 M Direct
Common Stock Disposition 2011-06-14 1,354 $8.20 3,960 No 4 S Direct
Common Stock Acquisiton 2011-06-14 4,487 $3.09 8,447 No 4 M Direct
Common Stock Disposition 2011-06-14 4,487 $8.20 3,960 No 4 S Direct
Common Stock Acquisiton 2011-06-14 17,493 $3.09 21,453 No 4 M Direct
Common Stock Disposition 2011-06-14 17,493 $8.20 3,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2011-06-14 1,354 $0.00 1,354 $1.83
Common Stock Stock Option Disposition 2011-06-14 4,487 $0.00 4,487 $3.09
Common Stock Stock Option Disposition 2011-06-14 17,493 $0.00 17,493 $3.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,083 2019-01-23 No 4 M Direct
16,122 2020-01-07 No 4 M Direct
31,898 2020-01-07 No 4 M Direct
Footnotes
  1. Shares were initially purchased under Depomed, Inc.'s 2004 Employee Stock Purchase Plan.
  2. Exercisable in 48 equal monthly installments.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.23 to $8.26. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each price within the range set forth in this footnote.